EU revises GMP guide on products derived from human blood, plasma
This article was originally published in RAJ Devices
Executive Summary
The European Commission has substantially revised its guidance on good manufacturing practice requirements for drugs derived from human blood or plasma that is fractionated in, or imported into, the EU/European Economic Area1,2. The updated guidance also applies to stable derivatives of human blood or human plasma (eg albumin) incorporated into medical devices.